Skip to main content
Top

Cellular Oncology

Issue 2/2020

Content (12 Articles)

HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer

Kim Jun Cheng, Mohammed Abdullah Alshawsh, Elsa Haniffah Mejia Mohamed, Surendran Thavagnanam, Ajantha Sinniah, Zaridatul Aini Ibrahim

Esophageal carcinoma: Towards targeted therapies

Ali Fatehi Hassanabad, Rania Chehade, Daniel Breadner, Jacques Raphael

Cholangiocarcinoma Original paper

CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion

Paweena Dana, Saowaluk Saisomboon, Ryusho Kariya, Seiji Okada, Sumalee Obchoei, Kanlayanee Sawanyawisuth, Chaisiri Wongkham, Chawalit Pairojkul, Sopit Wongkham, Kulthida Vaeteewoottacharn

Colon Cancer Original paper

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

Aziz Zaanan, Claire Calmel, Julie Henriques, Magali Svrcek, Hélène Blons, Christèle Desbois-Mouthon, Fatiha Merabtene, Claire Goumard, Yann Parc, Brice Gayet, Julien Taieb, Pierre Validire, Christophe Louvet, Jean-François Fléjou, Yves Le Bouc, Françoise Praz

Metastasis Original paper

MicroRNA-129-5p suppresses nasopharyngeal carcinoma lymphangiogenesis and lymph node metastasis by targeting ZIC2

Dan Yu, Guang-Hong Han, Xue Zhao, Xueshibojie Liu, Kai Xue, Di Wang, Cheng-Bi Xu

Open Access Hepatocellular Carcinoma Original paper

Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4

Chao Ye, Xiaoqian Zhang, Xinyu Chen, Qingyi Cao, Xiaobing Zhang, Yanwen Zhou, Wenxin Li, Liangjie Hong, Haiyang Xie, Xiaoli Liu, Hongcui Cao, Ying-Jie Wang, Bo Kang

Colon Cancer Original paper

Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4α and WNK2 regulation

Ting Xu, Kun Wu, Lei Zhang, Shutao Zheng, Xiaopeng Wang, Hao Zuo, Xu Wu, Guoquan Tao, Baofei Jiang, Li Zhang

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine